Pharmaron’s $588 Million Hong Kong IPO

O’Melveny represented Pharmaron Beijing Co., Ltd. (300759.SZ and 3759.HK), in its approximately HK$4.6 billion (approximately US$588 million) dual primary listing and H share offering in Hong Kong.

Based in Beijing, Pharmaron is a leading fully integrated pharmaceutical R&D service platform serving China and overseas pharmaceutical companies. Pharmaron established a leading position in drug discovery, pre-clinical and early clinical-stage development, while also expanding capabilities downstream to late clinical-stage development and commercial manufacturing.

The Joint Sponsors for the IPO are Goldman Sachs (Asia) LLC, CLSA Capital Markets Limited, and Orient Capital (Hong Kong) Limited.

The O’Melveny team was led by partners Portia Ku (Picture), Ke Zhu, and Edwin Kwok, and the team included counsel Vincent Lin, associates Wendy Kan, Aaron Xin, Yuki Tsang, and Edward Poon, trainee solicitor Darryl Wan, and legal consultant Tiffany Liu. Counsel Wenting Yu and Adam Ajlouni, and associates Sydney Ryan and Ying Li also provided valuable assistance.

Involved fees earner: Adam Ajlouni – O’Melveny & Myers LLP; Wendy Kan – O’Melveny & Myers LLP; Portia Ku – O’Melveny & Myers LLP; Edwin Kwok – O’Melveny & Myers LLP; Vincent Lin – O’Melveny & Myers LLP; Sydney Ryan – O’Melveny & Myers LLP; Yuki Tsang – O’Melveny & Myers LLP; Aaron Xin – O’Melveny & Myers LLP; Wenting Yu – O’Melveny & Myers LLP; Ke Zhu – O’Melveny & Myers LLP;

Law Firms: O’Melveny & Myers LLP;

Clients: Pharmaron;

Print Friendly, PDF & Email

Author: Michael Patrini